Skip to main content

Immunic, Inc. (IMUX)

NASDAQ: IMUX · IEX Real-Time Price · USD
8.67 0.28 (3.34%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap227.58M
Revenue (ttm)n/a
Net Income (ttm)-76.54M
Shares Out26.25M
EPS (ttm)-3.73
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume192,524
Open8.49
Previous Close8.39
Day's Range8.30 - 8.70
52-Week Range6.96 - 28.21
Beta1.94
AnalystsBuy
Price Target54.50 (+528.6%)
Est. Earnings DateNov 4, 2021

About IMUX

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intes...

IndustryBiotechnology
CEODaniel Vitt
Employees45
Stock ExchangeNASDAQ
Ticker SymbolIMUX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for Immunic stock is "Buy." The 12-month stock price forecast is 54.50, which is an increase of 528.60% from the latest price.

Price Target
$54.50
(528.60% upside)
Analyst Consensus: Buy

News

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic ...

2 days ago - PRNewsWire

Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis

NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic...

2 weeks ago - PRNewsWire

Immunic, Inc. to Participate in Scientific and Investor Conferences in October

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic...

2 weeks ago - PRNewsWire

Immunic, University Medical Center Goettingen Ink Licensing Pact For Combination Viral Infection Treatments

Immunic Inc (NASDAQ: IMUX) has executed an in-license agreement with the University Medical Center Goettingen covering the combination of DHODH inhibitors and nucleoside analogs to treat viral infection...

3 weeks ago - Benzinga

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibit...

NEW YORK and GOETTINGEN, Germany, Sept. 22, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies foc...

3 weeks ago - PRNewsWire

Immunic, Inc. to Participate in Investor and Scientific Conferences in September

NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic ...

1 month ago - PRNewsWire

Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity

NEW YORK, Aug. 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic i...

2 months ago - PRNewsWire

Immunic, Inc. to Participate in Investor Conferences in August

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic i...

2 months ago - PRNewsWire

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

NEW YORK, July 19, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on t...

2 months ago - PRNewsWire

Why Immunic Plummeted by 21% on Thursday

Word of a new share issue made investors feel queasy.

3 months ago - The Motley Fool

Immunic Stock Is Trading Lower After Equity Raise Of $45M To Fund Lead Pipeline Candidates

Immunic Inc (NASDAQ: IMUX) has priced an underwritten public offering of 4.5 million shares at $10 per share, representing a discount of about 16% from the last close price of $11.89 on Wednesday. The g...

3 months ago - Benzinga

Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock

NEW YORK, July 15, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on t...

3 months ago - PRNewsWire

Immunic, Inc. Announces Proposed Public Offering of Common Stock

NEW YORK, July 14, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on t...

3 months ago - PRNewsWire

Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-9...

NEW YORK, July 12, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic ...

3 months ago - PRNewsWire

Immunic Stock Jumps As FDA Signs Off On 2 Clinical Trial Applications

The FDA has signed off Immunic Inc's (NASDAQ: IMUX) investigational new drug application for the Phase 3 ENSURE program of lead asset IMU-838 in patients with relapsing-remitting multiple sclerosis.  In...

3 months ago - Benzinga

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Scleros...

NEW YORK, July 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammat...

3 months ago - PRNewsWire

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July

NEW YORK, June 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

3 months ago - PRNewsWire

Immunic, Inc. to Participate in Industry and Investor Conferences in June

NEW YORK, June 10, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic in...

4 months ago - PRNewsWire

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel

NEW YORK, June 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inf...

4 months ago - PRNewsWire

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity

NEW YORK, May 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammato...

5 months ago - PRNewsWire

Why PPD, Immunic, Inovio and CureVac Shares Are Higher Today

PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday.

Other symbols:CVACINO
6 months ago - Benzinga

Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remit...

NEW YORK, April 15, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflamm...

6 months ago - PRNewsWire

Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April

NEW YORK, April 13, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic i...

6 months ago - PRNewsWire

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838

NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology ther...

6 months ago - PRNewsWire

Immunic Gets Bullish Rating On Multiple Sclerosis Drug Prospect

Immunic Inc's (NASDAQ: IMUX) lead candidate, IMU-838, has an “attractive safety profile” and exhibited positive efficacy results in the Phase II trials, according to JMP Securities. The Immunic Analyst:...

6 months ago - Benzinga